Background. Among patients with index oropharyngeal cancer, second primary malignancies (SPMs) may be less common in cases of human papillomavirus (HPV)-associated tumors than HPVnegative tumors. Further modification of these SPM risks by smoking has not been reported. Methods. SPM outcomes of 356 patients with incident oropharyngeal cancer were analyzed using Cox proportional hazards and Kaplan-Meier models. SPM risk and SPM-free survival were compared in HPVseronegative patients, HPV-seropositive never smokers, and HPVseropositive ever smokers. Results. HPV-seropositive patients had a lower 5-year SPM rate than HPV-seronegative patients (5.6% vs 14.6%; p ¼ .051). Compared to HPV-seronegative patients, HPV-seropositive never smokers had a 73% reduced SPM risk, and HPV-seropositive ever smokers had a 27% reduced SPM risk (trend p ¼ .028). Although HPV-seronegative patients had SPMs in traditional locations, 70% of SPMs among HPV-seropositive patients were outside typical tobacco-related sites. Conclusion. HPV serologic status and smoking may stratify patients with index oropharyngeal cancers in terms of risk and location of SPMs.
INTRODUCTION
Squamous cell carcinoma of the head and neck (SCCHN) is one of the more common malignancies worldwide. 1 Advances in multidisciplinary care have improved survival rates of patients with index SCCHNs, yet the development of a second primary malignancy (SPM) remains a major cause of morbidity and mortality in this group. A recent large population-based study showed that patients with SCCHN have a high risk of developing an SPM, predominantly in the head and neck, lung, or esophagus. 2 SPMs account for most of the longterm morbidity in patients with SCCHN who live more than 3 years after diagnosis, 3 and survival after diagnosis of SPMs is notably poorer than survival after diagnosis of similar index cancers. [4] [5] [6] For this reason, optimal screening for SPMs is essential to the care of patients with SCCHN and represents a major survivorship issue. SCCHN is strongly associated with alcohol and tobacco use, but an epidemic of human papillomavirus (HPV)-associated squamous cell carcinoma of the oropharynx (SCCOP) has emerged over the past 2 decades. [7] [8] [9] [10] [11] [12] [13] [14] HPVassociated SCCOP commonly occurs in nonsmokers and younger patients and is associated with certain sexual practices. [14] [15] [16] Patients with HPV-positive SCCOP have better survival than those with HPV-negative tumors, 17 and HPV-positive SCCOP has clinical behavior different from that of the traditional smoking-or alcohol-associated malignancies. 18 Recent data suggest that the survival of patients with HPV-positive SCCOP can be refined further by smoking exposure. 17 Others 17, 18 have previously reported significantly lower rates of SPMs among patients with HPV-positive than HPV-negative SCCOP, but to our knowledge, the influence of smoking on SPM risk among patients who are HPV positive has not been reported.
It is crucial to elucidate how HPV-associated SCCOP compares with HPV-negative SCCOP so that physicians can effectively tailor treatment, screening, and follow-up strategies on the basis of patients' HPV status. We sought to determine the influence of HPV positivity and smoking status on the risk and locations of SPMs among patients with SCCOP. We conducted our study using a large database of patients with SCCHN treated at a tertiary cancer center in the United States.
MATERIALS AND METHODS

Study patients
This research was approved by the Institutional Review Board of The University of Texas MD Anderson Cancer Center. All patients were participants in a molecular epidemiologic protocol of incident SCCHN between 1995 and 2003. Patients were included if they had previously untreated, pathologically confirmed SCCOP (tonsil, base of tongue, soft palate/uvula, or posterior/lateral oropharyngeal wall; n ¼ 406). Patients who received a consultation alone without treatment at our center (n ¼ 36) were excluded from the analysis, as were patients who received only palliative care (n ¼ 14). After these exclusion criteria were applied, 356 patients remained for analysis.
Throughout their treatment and posttreatment courses, patients had regularly scheduled clinical and radiographic examinations with surgeons, radiation oncologists, and medical oncologists specializing in head and neck cancer. On the basis of modified criteria of Warren and Gates, 19 second lesions were considered SPMs if they were of different histopathologic type than the index tumor, occurred more than 5 years after treatment for the index tumor, or were clearly separated from the index tumor by normal epithelium based on clinical and radiographic assessment. Pulmonary lesions were considered to be SPMs if they had a nonsquamous histology or if they were isolated squamous lesions appearing greater than 5 years after the initial SCCHN and were believed to be SPMs by the thoracic medical oncologist and the thoracic surgeon. If there was a difference of opinion or question regarding the origin of any second lesion (ie, recurrence vs SPM), the second lesion was classified as a recurrence rather than an SPM. SPMs were then categorized as being in 1 of 3 classes: SCCHN, other tobacco-related cancer (lung and bronchus, esophagus, or urinary bladder), or other. Nonmelanoma skin cancers were not recorded or considered SPMs.
HPV status was determined via serologic methods as part of a research study of a sample of patients with oropharyngeal cancer between 1995 and 2003. Serologic methods have been described in detail previously and were based on an established assay for antibody response to HPV16 virus-like particles. 20 Prior studies have shown significant correlation between HPV seropositivity and the presence of HPV16 DNA within tumor tissue. 21 All patients completed a prospective standard epidemiologic questionnaire at time of enrollment, which included smoking and alcohol consumption data. Ever smokers were defined as those who had smoked more than 100 cigarettes in their lifetime, and ever drinkers were defined as those who had drunk alcoholic beverages at least once per week for over a year at any period in their lifetime. A subject's comorbidities were determined on the basis of his or her medical history at initial encounter and were scored using the Adult Comorbidity Evaluation 27, an index extensively used in studies of head and neck cancer. 22 
Statistical analysis
Analysis was done using Stata statistical software (release 12; StataCorp, College Station, TX). The threshold for statistical significance was set at p < .05, and all tests were 2-sided. Chi-square tests were used to assess differences in demographic and clinical variables between HPV-seronegative patients and HPV-seropositive patients and differences in HPV status among patients who developed SPM and those who did not. Cox proportional hazards models were generated to calculate hazard ratios (HRs) to detect any differences in SPM-free survival between groups. Multivariable models were created by minimizing Akaike's information criterion. Kaplan-Meier curves were generated and log-rank tests were performed to detect statistically significant differences in SPM-free survival. Time to event was calculated from the date of diagnosis of the index oropharyngeal cancer to the date of SPM occurrence. Patients without a known SPM at the date of last contact, those who were lost to follow-up, and those who died after their initial date of diagnosis were censored. Multiple imputation was used to account for potential bias in estimates due to missing HPV16 serologic status. We created 20 datasets using a Markov chain Monte Carlo algorithm, and Rubin's formula was used to combine the analyses (Stata Release 12 with Stata Multiple-Imputation Reference Manual: Release 12 online documentation, StataCorp).
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RESULTS
Of the 356 patients with incident oropharyngeal cancer who were treated at our institution between 1995 and 2003, 182 (51%) had HPV serologic test results available, and results were positive in 80 patients (44%). Among patients with HPV serologic test results available, the median follow-up time was 104 months for those still alive at last follow-up.
Risk of second primary malignancies by human papillomavirus status
Overall, HPV-seropositive patients had a lower 5-year SPM rate than HPV-seronegative patients (5.6% vs 14.6%; p ¼ .051; Table 1 ). The 5-year SPM rate was lower for HPV-seropositive patients than for HPV-seronegative patients in 11 of 12 demographic subgroups (Table 1) and 11 of 14 clinical subgroups (Table 2) . However, these differences were significant only for never smokers, patients having limited comorbidities, patients with moderate or poorly differentiated cancers, and patients treated with radiation alone (Tables 1 and 2 ).
In a Kaplan-Meier analysis, HPV-seropositive patients had better SPM-free survival than HPV-seronegative patients (p ¼ .051; Figure 1A ). HPV-seropositive patients had half the SPM risk of patients with HPV-seronegative (HR, 0.48; 95% confidence interval [CI], 0.23-1.02; p ¼ .056; Table 3 ). After multivariable adjustment, this lower risk was still apparent (30% reduced risk), although not significant (HR, 0.70; 95% CI, 0.31-1.57; p ¼ .382).
Risk of second primary malignancies by human papillomavirus and smoking status
In a Kaplan-Meier analysis, HPV-seropositive ever smokers had an SPM-free survival more similar to that of HPV-seronegative patients than to that of HPV-seropositive never smokers ( Figure 1B) . The HPV-seropositive never smokers, but not the HPV-seropositive ever smokers, had a significantly lower SPM rate and risk than HPV-seronegative patients (Table 3) . Furthermore, there was a significant trend of lower SPM rate and risk with the combination of HPV seropositivity and lack of smoking (Table 3) . Compared with HPV-seronegative patients, HPV-seropositive ever smokers had a 27% reduced SPM risk (HR, 0.73; 95% CI, 0.31-1.71; p ¼ .468), whereas HPV-seropositive never smokers had a Table 3 ). In order to explore whether these findings applied to all 356 patients enrolled and treated during the time period of study, multiple imputation analysis was used to impute missing HPV serologic status in the remaining 174 patients. Patients with complete data were compared to those with missing data across all variables, and no significant differences in the distribution of these variables were noted between groups (data not shown). Also, there were no statistically significant differences in the 5-year SPM rates between those with and without HPV data, or within any of their subgroups (data not shown). After multiple imputation analysis to account for missing HPV serologic data, HPV seropositivity was associated with a similar (although significant) magnitude reduction in SPM risk as was seen in patients with complete HPV data ( Table 3) . A significant trend for decreasing SPM risk with HPV-seropositivity and lack of smoking was found in both crude and adjusted analyses ( 
Locations of second primary malignancies by human papillomavirus and smoking status
Finally, SPM sites segregated by HPV serologic status and smoking are presented in Table 4 . HPV-seronegative patients tended to develop SPMs in more traditional sites, such as the head and neck, lung and bronchus, esophagus, and urinary bladder. However, 7 of the 10 SPMs among HPV-seropositive patients were located outside these traditional locations (Table 4) .
DISCUSSION
This study sheds light on the combined impact of HPV serologic status and smoking history on the risk of SPM among patients with index oropharyngeal cancer. Overall, HPV-seropositive patients had a lower risk of SPM than HPV-seronegative patients. However, HPV-seropositive patients with a history of smoking had SPM-free survival and risk profiles more similar to those of HPV-seronegative patients than to those of HPV-seropositive never smokers. † Adjusted for sex, grade, N classification, smoking, and comorbidity. ‡ P (trend) for HPVþ never smokers vs. HPVþ ever smokers versus HPV-.
Our findings regarding HPV serologic status are consistent with the concept that HPV-positive and HPV-negative oropharyngeal carcinomas are separate clinical entities, each with their own unique risk factors, clinical presentation, outcomes, and follow-up requirements. Our findings are in agreement with those of Ang et al 17 and Huang et al 18 who reported lower SPM rates among HPV-positive patients than among those with HPV-negative oropharyngeal cancers. HPV-positive tumors often arise in an environment with limited tobacco exposure and have fewer mutations and chromosomal abnormalities than HPV-negative tumors, which are typically smoking related. 26, 27 It would seem logical that the risks and locations of SPMs would differ between HPV-positive and HPV-negative index tumors as well. In fact, national data have demonstrated that while in the past, patients with index oropharyngeal cancer had very high SPM rates, similar to those of other SCCHN populations, more recently, patients with oropharyngeal cancer have the lowest SPM rates among SCCHN populations, apparently as a result of the emerging epidemic of HPV-associated oropharyngeal cancer. 28 Tobacco use is well known as the primary risk factor for the development of SCCHN and subsequent SPM. The concept of field cancerization associated with the use of tobacco products is well described and contributes to the increased risk of SPM among patients with SCCHN 2, 3 and also patients with HPV-negative oropharyngeal cancer, who, similar to traditional patients with SCCHN, tend to be older and more likely to have a smoking history than patients with HPV-positive oropharyngeal cancer. 29, 30 As expected, most of the SPMs in HPV-seronegative patients in our study developed in smokingassociated locations such as the head and neck, the lung and bronchus, the esophagus, and the urinary bladder. In contrast, HPV-seropositive patients had overall fewer SPMs and proportionally fewer SPMs in the traditional smoking-associated locations. Our findings regarding SPM locations in HPV-seronegative patients are similar to those of Ang et al 17 and Huang et al 18 : in all 3 studies, 63% to 75% of SPMs in patients with HPV-negative disease were found in the traditional smoking-associated locations (head and neck, lung and bronchus, esophagus, and bladder). 17, 18 When these 3 studies are taken together, only 46% (32 of 70) of SPMs among patients with HPV-associated disease occurred in smoking-associated locations. Although previous studies suggest that oropharyngeal cancers are also associated with SPMs at sites traditionally associated with HPV, such as the cervix, penis, and anus, 2,31 we did not observe any SPMs at anogenital sites, and only 2 anogenital cancers out of 60 SPMs were reported among patients with HPV-associated oropharyngeal cancer in the Ang et al 17 and Huang et al 18 reports. Whereas others 17, 18 have previously reported significantly lower rates of SPMs among patients with HPVassociated SCCOP than among patients with HPV-negative SCCOP, a difference in SPM risks or locations between patients with HPV-associated SCCOP with or without smoking exposures has not to our knowledge ever before been reported. In this cohort, HPV-seropositive never smokers had a 5-year SPM-free survival rate of 100%. These findings have important implications in terms of the follow-up care for patients with oropharyngeal cancer. Although our study did not evaluate overall survival as an endpoint, it is certainly possible that the lower SPM rates observed in patients with HPV-associated oropharyngeal cancer contribute, in part, to the wellknown excellent survival of these patients. 17 Other authors have previously shown that smokers with HPVpositive oropharyngeal cancer have lower overall and disease-specific survival rates than never smokers with HPV-positive oropharyngeal cancer, 32, 33 and this study confirms a similar effect in terms of SPM-free survival.
This study does have limitations that are important to recognize. Many of the results did not reach statistical significance despite trends in the data, likely because of our limited sample size. This limitation is counterweighted by strong follow-up in the study sample: every patient had at least 8 years of potential follow-up time, and the observed median follow-up time was 104 months. Another major limitation of this study was the use of HPV serologic methods to segregate SPM risk groups. While HPV serologic status does reflect past exposures, not all exposed patients will seroconvert or maintain an antibody response. It would be preferable to determine HPV status directly from tumor specimens by HPV in situ hybridization and measurement of p16 expression. Directly obtaining HPV status from tumor specimens is a more accurate way of classifying patients with cancer. Although we did not have tumor tissues from most patients from this period, one of our priorities for the future is to present our subsequent experience with SPM risk in a larger sample of patients with oropharyngeal cancer with both rigorous and lengthy follow-up and HPV status determined by testing of tumor tissues. We conclude that both HPV exposures and smoking influence the risks and locations of SPM development among patients with oropharyngeal cancer. Furthermore, these results suggest that although SPM risk may be particularly low among never smokers with HPV-associated oropharyngeal cancer, ever smokers with HPV-positive cancers may require more heightened awareness of SPM risk. Whereas we did not observe any SPMs at other sites associated with HPV among our patients, we believe that the existing literature suggests that clinicians following patients with HPV-associated oropharyngeal cancer should also be aware of the risk of anogenital SPMs.
